A Phase 1 interventional study of LY4560736 and LY4560736 in Healthy Volunteers, Alzheimer Disease and Amyloid, sponsored by Eli Lilly and Company. Not yet recruiting at 16 sites in 3 countries. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment
The purpose of this study is to see how safe LY4560736 is and to see how much and how quickly LY4560736 gets into the bloodstream. For healthy participants, the study also looks at how much LY4560736 gets into the brain. This part of the study lasts up to 13 weeks which includes staying in the Clinical Research Unit (CRU) for at least 4 days. This group will include Japanese participants, and the Sponsor may choose to enroll Chinese participants. For participants with Alzheimer's Disease, the study will also look at levels of a specific Alzheimer's-related protein in the brain and will last up to 13 weeks which includes staying in the CRU twice, each lasts about 1 to 2 days. Japanese participants, and potentially Chinese participants, may also be enrolled in this group.
Exclusion Criteria:
LY4560736 administered intravenously (IV) or subcutaneously (SC) in healthy volunteers.
Drug: LY4560736
Placebo administered IV or SC in healthy volunteers.
Drug: Placebo
LY4560736 administered IV to participants with AD. Florbetapir F 18 or Florbetaben F 18 will be administered IV during amyloid positron emission tomography (PET) scan.
Drug: LY4560736 · Other: Florbetapir F18 · Other: Florbetaben F 18
Placebo administered IV to participants with AD. Florbetapir F 18 or Florbetaben F 18 will be administered IV during amyloid PET scan.
Drug: Placebo · Other: Florbetapir F18 · Other: Florbetaben F 18
Administered intravenously (IV)
Administered subcutaneously (SC)
Administered IV
Administered SC
Administered IV
Administered IV
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Time frame: Baseline up to 13 Weeks
Pharmacokinetics (PK): Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity (AUC0-∞) Following a Single Dose of LY4560736 in Healthy Participants
Time frame: Baseline, Week 5
PK: Plasma LY4560736 Maximum Concentration at Steady State (Cmax,ss) in Participants with AD
Time frame: Baseline through Week 13
Concentration of LY4560736 in Cerebrospinal Fluid (CSF) in Healthy Participants
Time frame: Baseline through Study Completion (13 Weeks)
Change from Baseline of Amyloid Plaque levels as Assessed by Amyloid Positron Emission Tomography (PET) in Participants with AD
Time frame: Baseline through Study Completion (13 Weeks)
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eli Lilly and Company